Akan Emin1, Chris A Rogers2, Nicholas R Banner3. 1. Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK. 2. Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK. 3. Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, UK n.banner@rbht.nhs.uk.
Abstract
OBJECTIVES: Advanced chronic heart failure (ACHF) is progressive with poor prognosis and quality of life (QoL). Heart transplantation (HTx) is an effective treatment for ACHF, but is limited by scarcity of donor hearts. Left ventricular assist device (LVAD) support is a useful bridging therapy, and short- and medium-term outcomes have improved. We investigated QoL in patients assessed for HTx, awaiting HTx and after HTx. METHODS: We carried out a cross-sectional survey across four groups: Group 1-patients assessed for HTx, Group 2-patients listed for HTx on medical therapy, Group 3-patients supported with LVAD and Group 4-patients after HTx. Two questionnaires, the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EuroQol dimensions (EQ-5D), were administered in all adult HTx centres in the UK. Scores calculated for the KCCQ and EQ-5D were compared. RESULTS: Three hundred and eighty-six patients completed questionnaires: 194 in Group 1, 28 in Group 2, 82 in Group 3 and 82 in Group 4. Patients after HTx reported the best QoL [KCCQ overall summary score: mean 73.0 (SD 27.2)]; patients with LVAD reported better QoL than those being assessed for HTx and those listed for HTx on medical therapy [overall summary score; LVAD: 52.6 (22.0), Listed on medical therapy: 33.3 (21.1), ASSESSMENT: 35.5 (21.5)]. Similarly, EQ-5D scores were highest in patients after HTx [HTx: mean 0.74 (0.27); LVAD: 0.58 (0.26), Listed on medical therapy: 0.44 (0.27), ASSESSMENT: 0.50 (SD 0.30)]. CONCLUSIONS: Patients supported with LVAD had a significantly better QoL than those awaiting HTx without LVAD support, although HTx patients reported the best QoL.
OBJECTIVES: Advanced chronic heart failure (ACHF) is progressive with poor prognosis and quality of life (QoL). Heart transplantation (HTx) is an effective treatment for ACHF, but is limited by scarcity of donor hearts. Left ventricular assist device (LVAD) support is a useful bridging therapy, and short- and medium-term outcomes have improved. We investigated QoL in patients assessed for HTx, awaiting HTx and after HTx. METHODS: We carried out a cross-sectional survey across four groups: Group 1-patients assessed for HTx, Group 2-patients listed for HTx on medical therapy, Group 3-patients supported with LVAD and Group 4-patients after HTx. Two questionnaires, the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EuroQol dimensions (EQ-5D), were administered in all adult HTx centres in the UK. Scores calculated for the KCCQ and EQ-5D were compared. RESULTS: Three hundred and eighty-six patients completed questionnaires: 194 in Group 1, 28 in Group 2, 82 in Group 3 and 82 in Group 4. Patients after HTx reported the best QoL [KCCQ overall summary score: mean 73.0 (SD 27.2)]; patients with LVAD reported better QoL than those being assessed for HTx and those listed for HTx on medical therapy [overall summary score; LVAD: 52.6 (22.0), Listed on medical therapy: 33.3 (21.1), ASSESSMENT: 35.5 (21.5)]. Similarly, EQ-5D scores were highest in patients after HTx [HTx: mean 0.74 (0.27); LVAD: 0.58 (0.26), Listed on medical therapy: 0.44 (0.27), ASSESSMENT: 0.50 (SD 0.30)]. CONCLUSIONS:Patients supported with LVAD had a significantly better QoL than those awaiting HTx without LVAD support, although HTx patients reported the best QoL.
Authors: Zeliha Özdemir Köken; Ümit Kervan; Murat Avşar; Sinan Sabit Kocabeyoğlu; Mustafa Paç Journal: Turk Gogus Kalp Damar Cerrahisi Derg Date: 2020-04-22 Impact factor: 0.332
Authors: Kathleen L Grady; Adin-Cristian Andrei; Christian Elenbaas; Anna Warzecha; Abigail Baldridge; Andrew Kao; John A Spertus; Duc-Thinh Pham; Mary Amanda Dew; Eileen Hsich; William Cotts; Justin Hartupee; Salpy V Pamboukian; Francis D Pagani; Michael Petty; Brent Lampert; Maryl Johnson; Margaret Murray; Koji Takeda; Melana Yuzefpolskaya; Scott Silvestry; James K Kirklin; Clyde Yancy Journal: J Am Heart Assoc Date: 2022-02-12 Impact factor: 6.106
Authors: Crispino Tosto; Luigi Adamo; Heidi Craddock; Maria Di Blasi; Rosario Girgenti; Francesco Clemenza; Robert M Carney; Gregory Ewald Journal: Sci Rep Date: 2019-07-25 Impact factor: 4.379
Authors: Gian Luca Di Tanna; Michael Urbich; Heidi S Wirtz; Barbara Potrata; Marieke Heisen; Craig Bennison; John Brazier; Gary Globe Journal: Pharmacoeconomics Date: 2020-11-30 Impact factor: 4.981
Authors: Kathleen L Grady; Ike Okwuosa; Adin-Cristian Andrei; Tingqing Wu; Christian Elenbaas; Anna Warzecha; Abigail Baldridge; Michael Petty Journal: Transplant Direct Date: 2021-11-22
Authors: Luiz Fernando Rodrigues; Beatriz Robert Moreira; Alice Pereira Duque; Juliana Rega de Oliveira; Pedro Henrique Scheidt Figueiredo; Cláudia Rosa de Oliveira; Alexandre Siciliano Colafranceschi; Mauro Felippe Felix Mediano; Tereza Cristina Felippe Guimarães Journal: Braz J Cardiovasc Surg Date: 2022-08-16